Article Details

Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Rating of "Buy" from Brokerages

Retrieved on: 2020-11-06 07:39:56

Tags for this article:

Click the tags to see associated articles and topics

Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Rating of "Buy" from Brokerages. View article details on hiswai:

Excerpt

<b>Schonfeld Strategic Advisors</b> LLC now owns 171,527 shares of the company's stock valued at $2,434,000 after buying an additional 111,827 shares ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up